Parkside Financial Bank & Trust Purchases 325 Shares of DexCom, Inc. (NASDAQ:DXCM)

Parkside Financial Bank & Trust grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,009 shares of the medical device company’s stock after purchasing an additional 325 shares during the quarter. Parkside Financial Bank & Trust’s holdings in DexCom were worth $156,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the 4th quarter valued at about $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at about $38,000. Midwest Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at about $54,000. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom during the 3rd quarter valued at about $57,000. Finally, Rothschild Investment LLC increased its position in shares of DexCom by 250.5% during the 4th quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock valued at $58,000 after purchasing an additional 536 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DXCM shares. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $99.06.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 in the last quarter. 0.30% of the stock is owned by company insiders.

DexCom Trading Up 0.6 %

DXCM opened at $88.37 on Friday. The stock has a market cap of $34.53 billion, a PE ratio of 61.80, a PEG ratio of 2.30 and a beta of 1.14. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a 50 day moving average of $84.69 and a 200-day moving average of $76.71. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.